Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Tue, 19.11.2024
Formycon AG
Press Release // November 19, 2024
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, „Formycon“) invites to the conference call and webcast for the publication of the nine-month results 2024 on November 28, 2024. [ … ]
Mon, 18.11.2024
Formycon AG
Press Release // November 18, 2024
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of FYB203 for the treatment of Neovascular Age-Related [ … ]
Mon, 11.11.2024
Formycon AG
Press Release // November 11, 2024Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Dr. Stefan Glombitza has been appointed as CEO for three more years and will lead Formycon through the next phase of the company's development
Formycon shares will be admitt [ … ]
Mon, 04.11.2024
Formycon AG
Press Release // November 04, 2024
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
Application for admission to trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange will be submitted today
Trading of Formycon shares on the Prime Standard segment is expected to start on November 12, [ … ]
Wed, 16.10.2024
Formycon AG
Press Release // October 16, 2024
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
The comparative analytical evaluation results indicate that the proposed Keytruda®-biosimilar FYB206 is structurally and functionally highly similar to the reference [ … ]
Mon, 30.09.2024
Formycon AG
Press Release // September 30, 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
OtulfiTMreceived FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®
Approval represents the third successful FDA approval for a Formycon biosimilar, two of them in [ … ]
Fri, 27.09.2024
Formycon AG
Press Release // September 27, 2024Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
FYB202/Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Tue, 13.08.2024
Formycon AG
Press Release // August 13, 2024
Formycon reports a strong first half-year with multiple milestones achieved
Successful business development characterized by key operational, clinical, and regulatory milestones
Group revenue and EBITDA in line with expectations
Operating results of FYB201 in the first half of the year significantly exceeded ex [ … ]